NewAmsterdam Pharma Co N.V. (NAMS) Stock Profile — Insider Trades & Financials

Revenue$32.0K

Net Income-$74.9M

EPS$-1.72

Market Cap$3.9B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Michael Davidson

CEO & Executive Director

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimerâs disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Founded: 2019
Employees: 100
Headquarters: Naarden, 1411 DC, Netherlands

⚡

Core Efficiency

ROE?

-10.96%

ROA?

-9.74%

D/E Ratio?

0.13

Op. Margin?

-206187.50%

📊

Profitability Ratios

Net Margin?

-234134.38%

Loading company sections...

NewAmsterdam Pharma Co N.V.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness